Autologous CD19-directed CAR T-cell therapy composed of defined CD4+ and CD8+ T-cell subsets to target malignant B cells.
Autologous CD4+ and CD8+ T cells are engineered with a lentiviral vector to express a CD19-specific chimeric antigen receptor containing an anti-CD19 scFv, 4-1BB costimulatory domain, and CD3-zeta signaling domain. Upon binding CD19 on B-cell malignancies, the CAR activates T-cell cytotoxicity and proliferation to kill target cells. A truncated EGFR tag enables in vivo tracking and potential cetuximab-mediated elimination of the infused cells.
CD19-specific CAR T cells bind CD19 on target cells, triggering T-cell effector functions that kill via perforin/granzyme-mediated lysis and Fas–FasL-induced apoptosis.
Investigational intravenous bispecific T‑cell–redirecting antibody that binds BCMA on malignant plasma cells and CD3 on T cells to activate T‑cell–mediated cytotoxicity in multiple myeloma.
ABBV-383 (etentamig) is an IgG4 bispecific T-cell–redirecting antibody that binds BCMA on malignant plasma cells and CD3 on T cells, forming an immune synapse that activates cytotoxic T cells to kill BCMA-expressing myeloma cells, with a low-activating CD3 design to limit excess cytokine release.
Bispecific T-cell engager binds BCMA on tumor cells and CD3 on T cells, forming an immune synapse that activates cytotoxic T cells to kill BCMA+ cells via perforin/granzyme-mediated apoptosis.
Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy given as a single IV infusion to deplete CD19+ B-lineage cells in SLE.
Autologous T cells engineered to express an anti-CD19 chimeric antigen receptor with a 4-1BB costimulatory domain; after infusion, they recognize CD19 on B-lineage cells and induce cytotoxic killing, depleting B cells and plasmablasts to reduce autoantibody production and reset immune tolerance in SLE.
Anti-CD19 CAR-T cells bind CD19 on B-lineage cells and induce T-cell cytotoxicity (perforin/granzyme-mediated apoptosis and/or Fas–FasL), depleting CD19+ cells.
A bispecific T‑cell engager (BiTE) antibody construct that binds CD3 on T cells and CD19 on B‑lymphoblasts to redirect T‑cell cytotoxicity against CD19+ B‑ALL.
Bispecific T‑cell engager that binds CD3 on T cells and CD19 on B cells, bringing them into proximity to activate TCR signaling and redirect T‑cell cytotoxicity to lyse CD19‑expressing B‑lymphoblasts.
BiTE links CD3 on T cells to CD19 on target cells, activating T cells to form a cytolytic synapse and kill CD19+ cells via perforin/granzyme-mediated apoptosis.
Anti-HER2 monoclonal antibody that inhibits HER2 signaling and promotes antibody-dependent cellular cytotoxicity.
Humanized IgG1 monoclonal antibody targeting HER2 (ERBB2); binds the receptor extracellular domain to block HER2 signaling and dimerization, inhibit tumor cell proliferation, and trigger antibody-dependent cellular cytotoxicity (ADCC) via Fc gamma RIIIa (CD16)-expressing NK cells.
Trastuzumab binds HER2 on target cells and its Fc engages CD16 (FcγRIIIa) on NK cells to trigger ADCC, leading to lysis of HER2-expressing cells; it also inhibits HER2 signaling.